Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2892-2901

  Abduljalil, Khaled ^a,e   Kinzig, Martina ^b   Bulitta, Jürgen ^b,f   Horkovics Kovats, Stefan ^c   Sörgel, Fritz ^b,d   Rodamer, Michael ^b   Fuhr, Uwe ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Institute for Biomedical and Pharmaceutical Research   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e CERTARA UK LIMITED   (United Kingdom)

^f ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450 3A4;

ADULT; ARTICLE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POPULATION MODEL; PRIORITY JOURNAL; SIMULATION;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COMPUTER SIMULATION; FEMALE; HUMANS; MALE; MODELS, THEORETICAL; YOUNG ADULT;

EID: 67649984935     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01193-08     Document Type: Article

References (36)

1. Anderson, B. J., A. D. McKee, and N. H. Holford. 1997. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 33:313-327.
2. Bruce, M. A., S. D. Hall, B. D. Haehner-Daniels, and J. C. Gorski. 2001. In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab. Dispos 29:1023-1028.
3. Bulitta, J., S. Horkovics-Kovats, M. Borek, A. Skott, M. Illauer, M. Rodamer, M. Kinzig-Schippers, and F. Sörgel. 2003. Self-inhibition of clarithromycin's (CLA) metabolism in humans at steady-state, poster A-1625. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
4. Bulitta, J. B., S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51:2497-2507.
5. Chu, S., D. S. Wilson, R. L. Deaton, A. V. Mackenthun, C. N. Eason, and J. H. Cavanaugh. 1993. Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 33:719-726.
6. Chu, S. Y., R. Deaton, and J. Cavanaugh. 1992. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother. 36:1147-1150.
7. Chu, S. Y., G. R. Granneman, P. J. Pichotta, J. P. Decourt, J. Girault, and J. B. Fourtillan. 1993. Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics. J. Clin. Pharmacol. 33:480-485.
8. Chu, S. Y., L. T. Sennello, S. T. Bunnell, L. L. Varga, D. S. Wilson, and R. C. Sonders. 1992. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob. Agents Chemother. 36:2447-2453.
9. Craig, W. A., S. Kiem, and D. R. Andes. 2002. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin, abstr. A-1264. Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Davey, P. G. 1991. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J. Hosp. Infect. 19(Suppl. A):29-37.
11. Fernandes, P. B., R. Bailer, R. Swanson, C. W. Hanson, E. McDonald, N. Ramer, D. Hardy, N. Shipkowitz, R. R. Bower, and E. Gade. 1986. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob. Agents Chemother. 30:865-873.
12. Ferrero, J. L., B. A. Bopp, K. C. Marsh, S. C. Quigley, M. J. Johnson, D. J. Anderson, J. E. Lamm, K. G. Tolman, S. W. Sanders, J. H. Cavanaugh, and R. C. Sonders. 1990. Metabolism and disposition of clarithromycin in man. Drug Metab. Dispos 18:441-446.
13. Fraschini, F., F. Scaglione, and G. Demartini. 1993. Clarithromycin clinical pharmacokinetics. Clin. Pharmacokinet. 25:189-204.
14. Fuhr, U. 2008. Improvement in the handling of drug-drug interactions. Eur. J. Clin. Pharmacol. 64:167-171.
15. Gorski, J. C., D. R. Jones, B. D. Haehner-Daniels, M. A. Hamman, E. M. O'Mara, Jr., and S. D. Hall. 1998. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64:133-143.
16. Hung, I. F., A. K. Wu, V. C. Cheng, B. S. Tang, K. W. To, C. K. Yeung, P. C. Woo, S. K. Lau, B. M. Cheung, and K. Y. Yuen. 2005. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin. Infect. Dis. 41:291-300.
17. Ishii, K., Y. Saito, S. Itai, M. Nemoto, K. Takayama, and T. Nagai. 1998. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. Drug Dev. Ind. Pharm. 24:129-137.
18. Jones, R. N., M. E. Erwin, and M. S. Barrett. 1990. In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species. Eur. J. Clin. Microbiol. Infect. Dis. 9:846-848.
19. Langtry, H. D., and R. N. Brogden. 1997. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 53:973-1004.
20. Martin, S. J., C. G. Garvin, C. R. McBurney, and E. G. Sahloff. 2001. The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 47:581-587.
21. Mayhew, B. S., D. R. Jones, and S. D. Hall. 2000. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28:1031-1037.
22. Noreddin, A. M., D. Roberts, K. Nichol, A. Wierzbowski, D. J. Hoban, and G. G. Zhanel. 2002. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid freedrug concentrations. Antimicrob. Agents Chemother. 46:4029-4034.
23. Peters, D. H., and S. P. Clissold. 1992. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 44:117-164.
24. Petricoul, O., V. Cosson, E. Fuseau, and M. Marchand. 2007. Population models for drug absorption and enterohepatic recycling, p. 345-382. In E. I. Ette and P. J. Williams (ed.), Pharmacometrics: the science of quantitative pharmacology. John Wiley & Sons, Inc., Hoboken, NJ.
25. Pinto, A. G., J. Horlander, N. Chalasani, M. Hamman, A. Asghar, D. Kolwankar, and S. D. Hall. 2005. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br. J. Clin. Pharmacol. 59:440-446.
26. Pinto, A. G., Y. H. Wang, N. Chalasani, T. Skaar, D. Kolwankar, J. C. Gorski, S. Liangpunsakul, M. A. Hamman, M. Arefayene, and S. D. Hall. 2005. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin. Pharmacol. Ther. 77:178-188.
27. Plock, N., C. Buerger, C. Joukhadar, S. Kljucar, and C. Kloft. 2007. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab. Dispos. 35:1816-1823.
28. Rodrigues, A. D., E. M. Roberts, D. J. Mulford, Y. Yao, and D. Ouellet. 1997. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab. Dispos. 25:623-630.
29. Rodvold, K. A. 1999. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37:385-398.
30. Sturgill, M. G., and R. P. Rapp. 1992. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann. Pharmacother. 26:1099-1108.
31. Suzuki, A., I. Iida, M. Hirota, M. Akimoto, S. Higuchi, T. Suwa, M. Tani, T. Ishizaki, and K. Chiba. 2003. CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metab. Pharmacokinet. 18:104-113.
32. Tessier, P. R., M. K. Kim, W. Zhou, D. Xuan, C. Li, M. Ye, C. H. Nightingale, and D. P. Nicolau. 2002. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:1425-1434.
33. Traunmuller, F., M. Zeitlinger, P. Zeleny, M. Muller, and C. Joukhadar. 2007. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrob. Agents Chemother. 51:3185-3189.
34. Ushiama, H., H. Echizen, S. Nachi, and A. Ohnishi. 2002. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin. Pharmacol. Ther. 72:33-43.
35. Yamamoto, F., S. Harada, T. Mitsuyama, Y. Harada, Y. Kitahara, M. Yoshida, and Y. Nakanishi. 2004. Concentration of clarithromycin and 14-R-hydroxy-clarithromycin in plasma of patients with Mycobacterium avium complex infection, before and after the addition of rifampicin. Jpn. J. Antibiot. 57:124-133.
36. Zhou, S., S. Y. Chan, B. C. Goh, E. Chan, W. Duan, M. Huang, and H. L. McLeod. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44:279-304.